# Two Stage Study of Combination of Chemotherapy, SHR-1210 and/or Decitabine for Relapsed/Refractory PMBCLs

> **NCT03346642** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Chinese PLA General Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Primary Mediastinal Large B-cell Lymphoma

## Interventions

- **DRUG:** Decitabine
- **DRUG:** GVD chemotherapy
- **DRUG:** SHR-1210

## Key facts

- **NCT ID:** NCT03346642
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-05-01
- **Primary completion:** 2019-03-01
- **Final completion:** 2019-10-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2018-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03346642

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03346642, "Two Stage Study of Combination of Chemotherapy, SHR-1210 and/or Decitabine for Relapsed/Refractory PMBCLs". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03346642. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*